Merck Tops Q3 Estimates as Keytruda and Gardasil Drive Growth
Merck beat Q3 forecasts with $18.1B sales and $2.49 EPS. Keytruda and Gardasil powered results as the company raised its full-year outlook.
Merck beat Q3 forecasts with $18.1B sales and $2.49 EPS. Keytruda and Gardasil powered results as the company raised its full-year outlook.
Eli Lilly lifted its full-year revenue forecast to as much as $92 billion after strong Q3 sales of Mounjaro and Zepbound beat estimates, while trimming profit guidance on deal charges.
GSK beat Q3 sales and profit forecasts on strong specialty medicines, but shares fell as investors questioned the pipeline and restructuring.
Abbott will separate its Nutrition unit into an independent company by 2027 and lowered its 2026 sales growth outlook to about 6%.
J&J reports Q3 revenue of $25.4B and adjusted EPS of $2.59, beating estimates. Tremfya sales surge 68% while Middle East conflict weighs on medical device results.
UnitedHealth raised its 2026 EPS forecast to at least $20.50 after adjusted Q3 earnings of $4.69 beat estimates, helped by improved medical cost controls.